

B Douglas Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2827650/publications.pdf>

Version: 2024-02-01

64
papers

2,906
citations

230014

27
h-index

190340

53
g-index

64
all docs

64
docs citations

64
times ranked

4071
citing authors

#	ARTICLE	IF	CITATIONS
1	Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1340-1349.	0.5	5
2	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.2	4
3	Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2022, 63, 64-73.	0.6	11
4	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	3.2	70
5	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 259.e1-259.e11.	0.6	11
6	Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1660-1668.	0.6	10
7	Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 60-69.	3.2	17
8	CDK2-Mediated Upregulation of TNF α as a Mechanism of Selective Cytotoxicity in Acute Leukemia. <i>Cancer Research</i> , 2021, 81, 2666-2678.	0.4	5
9	Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot Study. <i>JCO Oncology Practice</i> , 2021, 17, e785-e793.	1.4	11
10	A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). <i>Leukemia and Lymphoma</i> , 2021, 62, 3181-3191.	0.6	4
11	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 616-629.	2.6	41
12	Infections in secondary immunodeficiency patients treated with Privigen [®] or Hizentra [®] : a retrospective US administrative claims study in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 3463-3473.	0.6	5
13	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory) Tj ETQq1 1 0.784314 rgBT /Over	0.7	1
14	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 175.	2.8	3
15	A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. <i>Leukemia Research</i> , 2021, 111, 106737.	0.4	4
16	Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. <i>Blood</i> , 2021, 138, 1846-1846.	0.6	0
17	Acute Leukemia and COVID-19: The Johns Hopkins Experience. <i>Blood</i> , 2021, 138, 4046-4046.	0.6	0
18	A Phase 1 Study of IRX195183, a RAR α -Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML. <i>Frontiers in Oncology</i> , 2020, 10, 587062.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	2.5	52
20	Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids. <i>Leukemia</i> , 2020, 34, 3077-3081.	3.3	14
21	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm. <i>Blood</i> , 2020, 136, 48-50.	0.6	0
22	Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
23	Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use. <i>Blood</i> , 2020, 136, 44-45.	0.6	0
24	Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL. <i>Blood</i> , 2020, 136, 42-44.	0.6	0
25	Analysis of Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 22-23.	0.6	1
26	Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP). <i>Blood</i> , 2020, 136, 17-18.	0.6	0
27	The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. <i>Clinical Therapeutics</i> , 2019, 41, 336-349.	1.1	16
28	Side effects from acute myeloid leukemia treatment: results from a national survey. <i>Current Medical Research and Opinion</i> , 2019, 35, 1965-1970.	0.9	33
29	Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. <i>Current Medical Research and Opinion</i> , 2019, 35, 1615-1622.	0.9	13
30	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1128-1135.	2.0	38
31	Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (>65 Years) AML Patients. <i>Blood</i> , 2019, 134, 832-832.	0.6	47
32	Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis. <i>Blood</i> , 2019, 134, 3841-3841.	0.6	1
33	Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 2801-2811.	0.6	9
34	Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML). <i>Leukemia Research</i> , 2018, 72, 92-95.	0.4	30
35	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 30-30.	0.6	7
36	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 391-400.	1.7	152

#	ARTICLE	IF	CITATIONS
37	A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission. <i>Journal of Palliative Medicine</i> , 2017, 20, 1267-1273.	0.6	8
38	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. <i>Blood</i> , 2017, 129, 1389-1393.	0.6	69
39	Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways. <i>Stem Cell Reviews and Reports</i> , 2017, 13, 17-23.	5.6	55
40	Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. <i>Stem Cells Translational Medicine</i> , 2017, 6, 840-850.	1.6	5
41	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	3.2	56
42	Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 78-82.	0.2	69
43	4EBP1/c-MYC/PUMA and NF- κ B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. <i>Blood</i> , 2016, 127, 2711-2722.	0.6	49
44	Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1172-1179.	1.7	93
45	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	0.6	259
46	Optimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 3001-3002.	0.6	0
47	An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7062-7062.	0.8	7
48	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 314-318.	2.0	103
49	Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon- γ (IFN) in newly diagnosed chronic myeloid leukemia (CML). <i>Leukemia Research</i> , 2014, 38, 886-890.	0.4	8
50	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014, 124, 3817-3827.	0.6	165
51	Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2012, 18, 5364-5373.	3.2	53
52	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Haematologica</i> , 2012, 97, 1736-1742.	1.7	65
53	Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. <i>British Journal of Haematology</i> , 2012, 158, 198-207.	1.2	7
54	Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. <i>Blood</i> , 2011, 117, 608-617.	0.6	69

#	ARTICLE	IF	CITATIONS
55	Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. <i>Blood</i> , 2011, 117, 3302-3310.	0.6	77
56	Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. <i>Leukemia Research</i> , 2011, 35, 87-94.	0.4	19
57	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Leukemia Research</i> , 2010, 34, 877-882.	0.4	78
58	K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2010, 16, 338-347.	3.2	106
59	Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2007, 13, 4467-4473.	3.2	87
60	Cancer Stem Cell Targeting in Multiple Myeloma by GRN163L, a Novel and Potent Telomerase Inhibitor.. <i>Blood</i> , 2006, 108, 2540-2540.	0.6	13
61	Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.. <i>Blood</i> , 2006, 108, 5309-5309.	0.6	0
62	Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. <i>British Journal of Haematology</i> , 2005, 130, 373-381.	1.2	87
63	Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias. <i>Clinical Cancer Research</i> , 2005, 11, 8403-8412.	3.2	84
64	Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2004, 103, 3669-3676.	0.6	593